Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with adalimumab or tofacitinib for moderate to severe RA. METHODS: Analyses inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., van Vollenhoven, Ronald F., Wilkinson, Bethanie, Wang, Lisy, Zwillich, Samuel H., Gruben, David, Biswas, Pinaki, Riese, Richard, Takiya, Liza, Jones, Thomas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918072/
https://www.ncbi.nlm.nih.gov/pubmed/27334658
http://dx.doi.org/10.1186/s13075-016-1049-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918072/
https://www.ncbi.nlm.nih.gov/pubmed/27334658
http://dx.doi.org/10.1186/s13075-016-1049-3

Ejemplares similares